Recent Updates
Recently added Catalysts
STAA Positive Sentiment

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

Thursday, September 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: STAAR Surgical Company has announced a $50 million share repurchase program approved by its Board of Directors. This initiative allows the company to buy back its outstanding common stock, potentially increasing shareholder value. The decision reflects the board's confidence in the company's financial health and future prospects.

Market Sentiment Analysis

POSITIVE FACTORS

  • Board approval indicates strong confidence in the company's future.
  • Share repurchase program may enhance shareholder value.
  • Company is financially stable to initiate a significant buyback.

Full Press Release Details

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Under its buyback program, STAAR may repurchase shares in the open market, through privately ne

Frequently Asked Questions

What is the amount authorized for the share repurchase?

The Board of Directors authorized a share repurchase program of up to $50 million.

What does the share repurchase program aim to achieve?

The program aims to enhance shareholder value through the buyback of outstanding shares.

Who approved the share repurchase program?

The share repurchase program was approved by STAAR Surgical's Board of Directors.

What type of lenses does STAAR Surgical specialize in?

STAAR Surgical specializes in phakic IOLs, particularly the EVO family of Implantable Collamer Lenses.

ShareAdd on Google
Tags: STAA Viatris Investor Conferences Healthcare STAAR Surgical share repurchase buyback program common stock
Last updated: Sep 24, 2026

Biotech snapshot

Cash runway
$181M liquidity · $0M/mo burn
Low dilution risk